Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.
Journal
European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
17
05
2021
accepted:
27
05
2021
pubmed:
21
6
2021
medline:
9
6
2022
entrez:
20
6
2021
Statut:
ppublish
Résumé
Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.
Identifiants
pubmed: 34147473
pii: S2588-9311(21)00114-0
doi: 10.1016/j.euo.2021.05.008
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-272Informations de copyright
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.